Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
Research
[키워드] 95% CI
adverse effect
adverse effects
Antiviral
Antiviral agents
clinical
Clinical improvement
conducted
control group
coronavirus
COVID-19
COVID-19 drug treatment
criteria
database
Deterioration
Efficacy and safety
Endpoint
enzyme
Favipiravir
FVP
Google Scholar
inhibit
less
Meta-analysis
Negative conversion
no significant difference
non-invasive ventilation
not significant
Oxygen requirement
oxygen support
profiles
purine
quantitative synthesis
radiological improvement
Randomized controlled trial
RCTs
Registered
Replication
Result
RNA
RNA polymerase
RNA virus
RT-PCR
searched
severe acute respiratory syndrome coronavirus-2
Side effect
Standard of care
statistically
supportive care
systematic review
Treatment
treatment for COVID-19
treatment group
two group
viral clearance
was done
[DOI] 10.1186/s12985-020-01412-z PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12985-020-01412-z PMC 바로가기 [Article Type] Research